A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Accurate blood-based biomarkers of Alzheimer's disease (AD) could constitute simple, inexpensive, and non-invasive tools for the early diagnosis and treatment of this devastating neurodegenerative disease. We sought to develop a robust AD biomarker panel by identifying alterations in plasma metabolites that persist throughout the continuum of AD pathophysiology. Using a multicenter, cross-sectional study design, we based our analysis on metabolites whose levels were altered both in AD patients and in patients with amnestic mild cognitive impairment (aMCI), the earliest identifiable stage of AD. UPLC coupled to mass spectrometry was used to independently compare the levels of 495 plasma metabolites in aMCI (n = 58) and AD (n = 100) patients with those of normal cognition controls (NC, n = 93). Metabolite alterations common to both aMCI and AD patients were used to generate a logistic regression model that accurately distinguished AD from NC patients. The final panel consisted of seven metabolites: three amino acids (glutamic acid, alanine, and aspartic acid), one non-esterified fatty acid (22:6n-3, DHA), one bile acid (deoxycholic acid), one phosphatidylethanolamine [PE(36:4)], and one sphingomyelin [SM(39:1)]. Detailed analysis ruled out the influence of potential confounding variables, including comorbidities and treatments, on each of the seven biomarkers. The final model accurately distinguished AD from NC patients (AUC, 0.918). Importantly, the model also distinguished aMCI from NC patients (AUC, 0.826), indicating its potential diagnostic utility in early disease stages. These findings describe a sensitive biomarker panel that may facilitate the specific detection of early-stage AD through the analysis of plasma samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Current concepts in mild cognitive impairment
Petersen, R. C., Doody, R., Kurz, A., Mohs, R. C., Morris, J. C., Rabins, P. V., Ritchie, K., Rossor, M., Thal, L., & Winblad, B. (2001) · Archives of Neurology · doi:10.1001/archneur.58.12.1985 · Cited by 4,781
Blessed, G., Tomlinson, B. E., & Roth, M. (1968) · British Journal of Psychiatry · doi:10.1192/bjp.114.512.797 · Cited by 4,117 · cited 2×
“Scale [26], the Hachinski Ischemic Score [27], and the”
Method. Cerebral blood flow in dementia.
Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Russell, R. W. R., & Symon, L. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510088009 · Cited by 3,186
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · cited 1×
“Memantine, a partial NMDA antagonist, stabilizes cognitive decline in patients with moderate-to-severe AD [41].”
BackgroundJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · cited 3×
“The 2011 revision of the criteria for the clinical diagnosis of AD, established by National Institute on Aging (NIA) and the Alzheimer’s Association (AA), incorporates biomarkers into the criteria for the first time [6].”
BackgroundMethodClassification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins
Ray, S., Britschgi, M., Herbert, C., Takeda-Uchimura, Y., Boxer, A., Blennow, K., Friedman, L. F., Galasko, D. R., Jutel, M., Karydas, A., et al. (2007) · Nature Medicine · doi:10.1038/nm1653 · Cited by 1,048 · cited 2×
“001 Range [min-max] [24–30] [16–30] [1–27] Gender % Female 53.”
BackgroundFagan, A. M., Roe, C. M., Xiong, C., Mintun, M. A., Morris, J. C., & Holtzman, D. M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.3.noc60123 · Cited by 897 · cited 2×
“918) to that reported for other blood and CSF biomarkers of AD [13, 19, 58–60].”
Background
Cited by
MahmoudianDehkordi, S., Arnold, M., Nho, K., Ahmad, S., Jia, W., Xie, G., Louie, G., Kueider‐Paisley, A., Moseley, M. A., Thompson, J. W., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.217 · Cited by 706
Neuroprotective Actions of Dietary Choline
Blusztajn, J., Slack, B., & Mellott, T. (2017) · Nutrients · doi:10.3390/nu9080815 · Cited by 293
Wu, L., Han, Y., Zheng, Z., Peng, G., Liu, P., Yue, S., Zhu, S., Chen, J., Lv, H., Shao, L., et al. (2021) · Nutrients · doi:10.3390/nu13010228 · Cited by 227
Microbial-derived metabolites as a risk factor of age-related cognitive decline and dementia
Connell, E., Le Gall, G., Pontifex, M. G., Sami, S., Cryan, J. F., Clarke, G., Müller, M., & Vauzour, D. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00548-6 · Cited by 208
“DCA has been previously linked with the presence of cognitive symptoms [127] and can modulate mitochondrial pathways causing apoptosis in a variety of tissues and cell types [128].”
BackgroundRole of diet and its effects on the gut microbiome in the pathophysiology of mental disorders
Horn, J., Mayer, D. E., Chen, S., & Mayer, E. A. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01922-0 · Cited by 193
“In another study that compared the metabolic profiles of AD, patients to those of healthy controls found the BA deoxycholic acid to be a part of the characteristic metabolites in early diagnosis of AD [80].”
Result
Metadata
- Authors
- Olazarán, J., Gil-de-Gómez, L., Rodríguez-Martín, A., Valentí-Soler, M., Frades-Payo, B., Marín-Muñoz, J., Antúnez, C., Frank-García, A., Acedo-Jiménez, C., Morlán-Gracia, L., Petidier-Torregrossa, R., Guisasola, M. C., Bermejo-Pareja, F., Sánchez-Ferro, Á., Pérez-Martínez, D. A., Manzano-Palomo, S., Farquhar, R., Rábano, A., & Calero, M.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2015-04-13
- Volume
- 45
- Issue
- 4
- Pages
- 1157-1173
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1509269112
- Cited by
- 115
- References
- 24
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease. https://app.cochat.ai/papers/10.3233/jad-142925
- The paper
- Olazarán, J., Gil-de-Gómez, L., Rodríguez-Martín, A., Valentí-Soler, M., Frades-Payo, B., Marín-Muñoz, J., Antúnez, C., Frank-García, A., Acedo-Jiménez, C., Morlán-Gracia, L., Petidier-Torregrossa, R., Guisasola, M. C., Bermejo-Pareja, F., Sánchez-Ferro, Á., Pérez-Martínez, D. A., Manzano-Palomo, S., Farquhar, R., Rábano, A., & Calero, M. (2015). A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-142925
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.